Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Safety

Adverse Effects

Regulators Move to Strip Approval of Tavneos After Trial Misconduct and Liver Safety Signals

The move could remove Tavneos from markets, upend care for current patients, increase scrutiny of clinical trial oversight.

Kissei Tells Japan Doctors to Halt New Tavneos Use After 20 Deaths Reported

Lilly’s Oral Foundayo Matches Insulin on Heart Safety in Major Diabetes Trial

FDA Flags 76 Liver Injuries Linked to Amgen’s Tavneos, Urges Tight Monitoring

FDA Warns Novo Nordisk Over Missed Reporting of Serious Semaglutide and GLP-1 Adverse Events

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

FDA Restricts Moderna and Novavax COVID-19 Vaccines to Seniors and Vulnerable Groups

UK Regulator Probes Pancreatitis Cases Linked to GLP-1 Weight-Loss Drugs